Last edition
News about "Dual Orexin Receptor Antagonist "
Eisai seeks UK Approval for Insomnia Therapy Lemborexant
Eisai has submitted lemborexant for regulatory review in the UK, aiming to expand treatment options for adults suffering from chronic insomnia and improve patients' daytime functioning.
Dual Orexin Receptor Antagonist | 04/07/2026 | By News Bureau
Eisai seeks UK Approval for Insomnia Therapy Lemborexant
Eisai has submitted lemborexant for regulatory review in the UK, aiming to expand treatment options for adults suffering from chronic insomnia and improve patients' daytime functioning.
Dual Orexin Receptor Antagonist | 04/07/2026 | By News Bureau
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan
QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.
Dual Orexin Receptor Antagonist | 19/12/2024 | By Aishwarya | 404
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy